Morgan Keegan

In a recent research report published by Morgan Keegan, St. Jude Medical, Inc.'s (NYSE: STJ) Riata lead is undergoing a FDA Class I recall because of an insulation issue. In the report, Morgan Keegan said, “St. Jude and Societal recommendations suggest that physicians leave the leads alone and...

Morgan Keegan has published a research report on Inergy (NYSE: NRGY) and has downgraded the company from Outperform to Market Perform. In the report, Morgan Keegan writes, "Inergy, LP (NRGY) held its distribution at $0.705/unit for its December quarter but in the press release accompanying the...

Morgan Keegan has downgraded Inergy (NYSE: NRGY) from Outperform to Market Perform and has lowered the price target from $29 to $18.

This is only a test

Morgan Keegan maintains its Outperform rating on Delek (NYSE: DK) and lowers its price target by $5 to $20 a share on preliminary loss posted by the company. Shares are still viewed as an opportunity for value investors. Morgan Keegan says, " DK released preliminary Q4 EPS results ranging from ($...

Morgan Keegan lowers its rating on Juniper (NYSE: JNPR) to Perform from Outperform and lowers its price target by $5 to $20 as 2012 growth is called into question following the company's lowered guidance. Morgan Keegan comments, " Slowing service provider spending coupled with a challenging macro...

Morgan Keegan has raised the price target on Swift Transportation (NYSE: SWFT) from $11 to $14 and maintains its Outperform rating.

Morgan Keegan has downgraded Juniper Networks (NASDAQ: JNPR) from Outperform to Market Perform and has lowered the price target from $25 to $20.

Morgan Keegan has downgraded Trustmark Corporation (NASDAQ: TRMK) from Outperform to Market Perform after shares closed yesterday within 2% of its $25 price target. In the report, Morgan Keegan writes, "We believe that TRMK remains well positioned to benefit from an ongoing US economic recovery,...

According to Morgan Keegan, Citrix Systems (NASDAQ: CTXS) price target is lowered to $80. Morgan Keegan said that CTXS announced 4Q11 results with EPS of $0.78 and $619.4 million in revenue (+17% Y/Y), compared to the consensus expectation for EPS of $0.76 and $618.8 million in revenue. “Overall,...

Morgan Keegan has downgraded Trustmark Corporation (NASDAQ: TRMK) from Outperform to Market Perform with a $25 price target.

Morgan Keegan has lowered the price target on WW Grainger (NYSE: GWW) from $239 to $231 and maintains its Outperform rating.

Morgan Keegan has lowered the price target on Citrix Systems (NASDAQ: CTXS) from $85 to $80 and maintains its Outperform rating.

Morgan Keegan reiterates its Outperform rating on Monro Myffler Brake (NASDAQ: MNRO) and raises its price target by $5 to $47 as the company beat estimates on OSG&A leverage. Morgan Keegan says, "We are encouraged by MNRO's ability to increase EPS by 20% on a flat comp. While weather and...